Picard Medical Hosts First Annual Business Update Call

Picard Medical, Inc. ( (PMI) ) has issued an update.

On March 25, 2026, Picard Medical held its first annual business update and earnings conference call to review financial and operating results for the year ended December 31, 2025. Management outlined the company’s mission, strategic overview, technology pipeline, operational strategy and financial performance, supported by clinical and patient perspectives on the SynCardia Total Artificial Heart, signaling an effort to reinforce its positioning in mechanical circulatory support and provide greater transparency to investors and clinicians.

The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.

Spark’s Take on PMI Stock

According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.

The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.

To see Spark’s full report on PMI stock, click here.

More about Picard Medical, Inc.

Picard Medical, Inc., listed on the NYSE American as PMI, operates in the medical device sector through its wholly owned subsidiary SynCardia Systems, LLC. The company focuses on heart replacement solutions, including the SynCardia Total Artificial Heart, which is currently approved for sale in the U.S. and Canada and positioned as an alternative to heart transplantation.

Average Trading Volume: 786,500

Technical Sentiment Signal: Strong Sell

Find detailed analytics on PMI stock on TipRanks’ Stock Analysis page.